Supercomputing 2024: ALAFIA Unveils Personal Supercomputers for Precision Medicine & AI

Alafia AI, Inc. (“ALAFIA”), a leader in omics computing and precision medicine, is today unveiling an expansion of its high-performance computing (HPC) product line to address the growing demand for scalable, heterogeneous computing in the biopharmaceutical and application development industries.…

Read MoreSupercomputing 2024: ALAFIA Unveils Personal Supercomputers for Precision Medicine & AI

CapeStart Launches MadeAi™: GenAI Platform for Life Sciences

At the ISPOR Europe 2024 Conference, CapeStart, Inc. unveiled MadeAi™, a generative AI-powered platform designed to revolutionize the synthesis of clinical information. The platform’s first solution, MadeAi-LR, enhances the efficiency of systematic literature reviews (SLRs), clinical evidence reports (CERs), meta-research,…

Read MoreCapeStart Launches MadeAi™: GenAI Platform for Life Sciences

Adicet Bio Presents Biomarker Data for Off-the-Shelf CAR T Therapy at ACR Convergence 2024

Adicet Bio, Inc. (Nasdaq: ACET), a clinical-stage biotechnology company focused on developing allogeneic gamma delta T cell therapies for autoimmune diseases and cancer, today announced that clinical biomarker data from the ADI-001 Phase 1 GLEAN trial will be presented in…

Read MoreAdicet Bio Presents Biomarker Data for Off-the-Shelf CAR T Therapy at ACR Convergence 2024

Alnylam Reports Interim Phase 1 Data on Nucresiran Showing Rapid, Sustained TTR Knockdown After One Dose

Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), a leader in RNA interference (RNAi) therapeutics, today announced positive new results from its ongoing Phase 1 clinical trial of nucresiran (formerly ALN-TTRsc04), an investigational RNAi therapeutic targeting transthyretin (TTR) for the treatment of ATTR…

Read MoreAlnylam Reports Interim Phase 1 Data on Nucresiran Showing Rapid, Sustained TTR Knockdown After One Dose